Ascelia Pharma AB
F:7ZA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascelia Pharma AB
F:7ZA
|
SE |
|
Progressive Planet Solutions Inc
F:ARB3
|
CA |
|
Canaan Inc
F:35J
|
SG |
Intrinsic Value
The intrinsic value of 
Ascelia Pharma AB (7ZA) under the Base Case is 0.0677 EUR per share.
Compared with the current market price of 0.0375 EUR, the stock appears
Undervalued by 45% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Ascelia Pharma AB Does
Ascelia Pharma is a Swedish biotech company that develops medicines for rare cancer-related conditions. Its lead project is Orviglance, an oral contrast agent designed to improve liver MRI scans for patients who cannot use standard gadolinium-based contrast agents, such as people with serious kidney problems. The company is still focused on development and regulatory work rather than broad commercial sales.
- Headquarters
- Sweden SE
- Employees
- 21
- IPO date
- Mar 13, 2019
Revenue & Expenses Breakdown
Ascelia Pharma AB
Earnings Waterfall
Ascelia Pharma AB
The intrinsic value for Ascelia Pharma AB (7ZA) under the Base Case is 0.0677 EUR.
Compared with the current market price of 0.0375 EUR, the stock appears Undervalued by 45% .